{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '1. Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant', 'may require reduction in order to maintain satisfactory therapeutic', 'hypoprothrombinemia.', '2. Concurrent administration of oxyphenbutazone and androgens may result in elevated', 'serum levels of oxyphenbutazone.', '3. In diabetic patients, the metabolic effects of androgens may decrease blood glucose', 'and, therefore, insulin requirements.', 'Drug/Laboratory test interferences', 'Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4', 'serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain', 'unchanged, however, and there is no clinical evidence of thyroid dysfunction.', 'Adverse Reactions', 'The following adverse reactions in the male have occurred with some androgens:', '1. Endocrine and urogenital: Gynecomastia and excessive frequency and duration of', 'penile erections. Oligospermia may occur at high dosages.', '2. Skin and appendages: Hirsutism, male pattern of baldness, seborrhea, and acne.', '3. Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium,', 'calcium, and inorganic phosphates.', '4. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely', 'hepatocellular neoplasms and peliosis hepatis.', '5. Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on', 'concomitant anticoagulant therapy, and polycythemia.', '6. Nervous system: Increased or decreased libido, headache, anxiety, depression, and', 'generalized paresthesia.', '7. Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.', '8. Miscellaneous: Inflammation and pain at the site of intramuscular injection.', 'Drug Abuse and Dependence', 'Controlled Substance Class:', 'Testosterone is a controlled substance under the Anabolic Steroids Control Act, and', 'testosterone have been assigned to Schedule III.', 'Overdosage', 'There have been no reports of acute overdosage with the androgens.', 'Administration', 'Testosterone injections are for intramuscular use only. It should not be given intravenously.', 'Intramuscular injections should be given deep in the gluteal muscle.', 'Supply', '61(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Testosterone is commercially available. It will be purchased for the study through the', 'SCCA/UWMC pharmacy and billed to the trial.', 'Testosterone Enanthate Injection, USP, 200 mg/mL is available as:', '5', 'mL Multiple Dose vial, Cartons of 1 vial NDC 0143-9750-01', 'Testosterone Cypionate Injection, USP, 200 mg/mL is available as:', '10 mL Multiple Dose vial, Cartons of 1 vial NDC 0574-0820-10', '8.2.4', 'Olaparib Labelling', 'Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local', 'regulatory guidelines. The labels will fulfill GMP Annex 13 requirements for labelling.', 'Label text will be translated into local language.', 'Each bottle of olaparib will have an investigational product label permanently affixed to the', 'outside stating that the material is for clinical trial/investigational use only and should be kept', 'out of reach of children. The label will include the dosing instructions and a space for the', 'enrollment code (E-code) to be completed at the time of dispensing.', 'The label will include the following information:', 'blank lines for quantity of tablets to be taken', 'enrollment code (E-code)', 'date of dispensing', 'Instructions stating that the olaparib tablets should be taken at approximately the same', 'time each morning and evening', '8.2.5', 'Storage', 'All study drugs should be kept in a secure place under appropriate storage conditions. For', 'olaparib, the investigational product label on the bottle and the Investigator Brochure specifies', 'the appropriate storage. Testosterone vials should be stored at controlled room temperature', '20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F [see USP]. Protect from light. Use carton to protect contents', 'from light until used.', '8.2.6', 'Management of toxicity of olaparib', 'Any toxicity observed during the course of the study could be managed by interruption of the', 'dose of study treatment or dose reductions. Repeat dose interruptions are allowed as required,', 'for a maximum of 4 weeks on each occasion. If the interruption is any longer, the study team', 'must be informed. Study treatment can be dose reduced to 250 mg twice daily as a first step', 'and to 200 mg twice daily as a second step. If the reduced dose of 200 mg twice daily is not', 'tolerable, no further dose reduction is allowed and study treatment should be discontinued.', '62(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}